Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-09
1999-11-23
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514422, 514443, A61K 31445, A61K 3140, A61K 3138
Patent
active
059901292
ABSTRACT:
The current invention provides methods for the up-regulation of trkA in a mammal, including humans, comprising the administration of an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.3 are, independently, --H, --CH.sub.3, --CO(C.sub.1 -C.sub.6 alkyl), or --COAr, where Ar is optionally substituted phenyl;
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5075321 (1991-12-01), Schreiber
patent: 5434166 (1995-07-01), Glasebrook
patent: 5441947 (1995-08-01), Dodge et al.
patent: 5445941 (1995-08-01), Yang
patent: 5482927 (1996-01-01), Maniar et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5494929 (1996-02-01), Grese
patent: 5504094 (1996-04-01), Bruns, Jr. et al.
patent: 5512296 (1996-04-01), Cullinan
patent: 5545647 (1996-08-01), Tanaka et al.
patent: 5686476 (1997-11-01), May
Draper et al., "Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Bryant et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;".Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al. "Uterine Bioassay of Tamoxifen, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458, 1980.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103, 1981.
Black et al., "Evidence for Biological Action of the Antiestrogens LY1107018 and Tamoxifen by Different Mechanisms," Endocrinology 109;1981, 987-989, 1981.
Black, L.J. "Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M.K. Agarwal ed.).
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, Jun. 8-10, 1983, abs. 93.
Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32, 1983, 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl)ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22, 1979, 962-966.
Black et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)etho xy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.
Metzger, et al. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence Journal of Clinical Endocrinology and Metabolism, vol. 79(2), 1994, 513-518.
Weissberger, et al., Activation of the Somatotropic Axis by Testosterone in Adult Males: Evidence for the Role of Aromatization, Journal of Clinical Endocrinology and Metabolism, vol. 76(6), 1407-1412, 1993.
Metzger, et al., Androgen Receptor Blockade with Flutamide Enhances Growth Hormone Secretion in Late Pubertal Males: Evidence for Independent Actions of Estrogen and Androgen, Journal of Clinical Endocrinology and Metabolism, vol. 76(5), 1993, 1147-1152.
Evans, et al., Effects of Sex and Age on the 24-Hour Profile of Growth Hormone Secretion in Man: Importance of Endogenous Estradiol Concentrations,Journal of Clinical Endocrinology and Metabolism, vol. 64(1) 1987.
Spijkstra, et al., Divergent Effects of the Antiestrogen Tamoxifen and of Estrogens on Luteinzing Hormone (LH) Pulse Frequency, But Not on Basal LH Levels and LH Pulse Amplitude in Men,, Journal of Clinical Endocrinology and Metabolism, vol. 64(1), 1987.
Caruso-Nicoletti, et al., Short Term, Low Dose Estradiol Accelerates Ulnar Growth in Boys, J. Clin. Endocrinol. Metabolism, vol. 61(5), 1985.
Database US Patfull on STN, No. 96:36299, Cullinan et al., of the abstract to U.S. Patent No. 5,512,296, Issued on Apr. 20, 1995.
Miranda et al, Chemical Abstracts, vol. 122, abstract No. 205433, 1994.
Frolik et al, Chemical Abstracts, vol. 125, abstract No. 185773, 1996.
Bryant Henry Uhlman
Santerre Robert Frank
Boudreaux William R.
Eli Lilly and Company
Jarvis William R. A.
Sales James J.
LandOfFree
Methods for regulating trkA expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for regulating trkA expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for regulating trkA expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1222273